STTK NASDAQ
Shattuck Labs, Inc.
1W: -8.7%
1M: -21.4%
3M: +51.9%
YTD: +64.2%
1Y: +491.3%
3Y: +129.8%
5Y: -77.3%
$6.10
+0.01 (+0.16%)
Weekly Expected Move ±9.0%
$5
$6
$6
$7
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$292.2M
52W Range0.712-8.33
Volume332,249
Avg Volume600,776
Beta1.19
Dividend—
Analyst Ratings
Company Info
CEOTaylor H. Schreiber
Employees44
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-09
Websiteshattucklabs.com
500 West 5th Street
Austin, TX 78703
US
Austin, TX 78703
US
512 900 4690
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Latest News
Shattuck Labs GAAP EPS of -$0.13 in-line
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
12 Health Care Stocks Moving In Wednesday's After-Market Session
Shattuck Labs Q1 EPS Forecast Increased by HC Wainwright
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Stout Stephen | A-Award | 12,805 | $1.08 | 2026-05-15 |
| Stout Stephen | M-Exempt | 12,805 | $1.08 | 2026-05-15 |
| Neill Andrew R | A-Award | 64,027 | $1.08 | 2026-05-12 |
| Neill Andrew R | M-Exempt | 64,027 | $1.08 | 2026-05-12 |
| Shukla Abhinav A. | M-Exempt | 2,032 | $3.57 | 2026-05-12 |